Anastassia Amaro, MD
Obesity Medicine, Diabetes, Endocrinology
Accepting new patients
Sees patients age 18 and up
Penn Endocrinology Perelman
View 3 additional locations
Schedule onlineCall 215-662-2300
Headshot of Anastassia Amaro, MD
Penn Medicine Provider

About me

  • Medical Director, Penn Metabolic Medicine
  • Professor of Clinical Medicine (Endocrinology, Diabetes and Metabolism)

Education and training

  • Medical School: First Moscow Sechenov Medical Institute
  • Residency: Advocate Lutheran General Hospital
  • Fellowship: Barnes-Jewish Center for Outpatient Health

What my patients think about me

Average Rating

405 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

February 2026
listened to my concerns
January 2026
knowledgeable, empathetic
January 2026
she's a great dr
January 2026
Dr. Amaro is fantastic and has helped along my weight loss journey

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Amaro is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Authors: Ryan R. Armbruster, Neil E. Wilson, Yvette Frimpong, Anne Cappola, Anastassia Amaro, Ravinder Reddy CrCEST Measures OXPHOS Improvement and Creatine Decrease following GLP-1 induced weight loss at 7T with 1H-MRS , Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition: 2026

Ryan R. Armbruster, Neil E. Wilson, Aylin Ergin, Anne Cappola, Anastassia Amaro, Ravinder Reddy Lipid and Acetyl Carnitine Differences measured before and after GLP-1 induced weight loss at 7T with 1H-MRS , Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition: 2026

Wonkyung Choi, Young-Hoon Nho, Liming Qiu, Andrew Chang, Gustavo Campos, Robert L. Seilheimer, W. Bryan Wilent, David Bakalov, Nida Firdous, Marie Kerr, Disha Joshi, Gabriella Maze, Uros Topalovic, Daniel Batista, Nanthia Suthana, Anastassia Amaro, Matthew R. Hayes, Iahn Cajigas, Mario Cristancho, Kelly C. Allison, Bijan Pesaran, Katherine W. Scangos, Joshua I. Gold, Thomas A. Wadden & Casey H. Halpern Brain activity associated with breakthrough food preoccupation in an individual on tirzepatide , Nature Medicine: 2025

Marianne Riordan, Anastassia Amaro Glucagon-Like Peptide-1 Receptor Agonists in Post-Bariatric Hypoglycemia: A Retrospective Chart Review , 32nd European Congress on Obesity: 2025

Caturano A, Amaro A, Berra CC, Conte C. Sarcopenic obesity and weight loss-induced muscle mass loss , Curr Opin Clin Nutr Metab Care: 2025

Emily Gleason, BA Lindsay Levine, BA ∙ Iris T. Lee, MD MSCE ∙ Nathanael Koelper, MPH ∙ Anastassia Amaro, MD ∙ Anuja Dokras, MD, MHCI, PhD Effect of Glucagon-Like Peptide 1 Agonist Medications on Weight Loss in Patients with and Without Polycystic Ovary Syndrome , Fertility and Sterility: 2025

Ariana M Chao 1, Simeon Taylor 2, Molly Moore 3, Anastassia Amaro 4, Thomas A Wadden 3 Evolving Approaches for Pharmacological Therapy of Obesity , Annu Rev Pharmacol Toxicol : 2025

Thomas A Wadden, Ariana M Chao, Molly Moore, Jena S Tronieri, Adam Gilden, Anastassia Amaro, Sharon Leonard, John M Jakicic The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities , Curr Obes Rep: 2023

Authors: Emily Gleason BA, Lindsay Levine BA, Iris T. Lee, MD, Nathanael Koelper, MPH, Anastassia Amaro, MD, Anuja Dokras, MD, MHCI, PhD Effect of Glucagon-Like Peptide 1 Receptor Agonist Pharmacotherapy on Weight Loss in Patients with and Without Polycystic Ovary Syndrome , ASRM 2023 Scientific Congress: 2023

R. Jones Jr, C. Maskart, J. Radway, A. Amaro, S. Cardillo A Multimodal Curriculum to Improve Medical Student Gender-affirming Communication Skills, poster presentation. , ENDO Society : 2023